FDA Approves MERCAPTOPURINE — Nova Laboratories, Ltd

Nova Laboratories has received FDA approval for the oral formulation of mercaptopurine (NDA205919), expanding an existing treatment portfolio during the vulnerable window of pediatric acute lymphoblastic leukemia remission maintenance. This approval offers Nova a valuable market entry point to compete against dominant generic makers, potentially increasing its financial value as a key component of standard chemotherapy protocols.